Literature DB >> 762115

Active carrier-mediated transport of melphalan by two separate amino acid transport systems in LPC-1 plasmacytoma cells in vitro.

G J Goldenberg, H Y Lam, A Begleiter.   

Abstract

Previous studies have shown that uptake of several alkylating agents occurs by independent transport mechanisms. Uptake of one of these agents, the phenylalanine derivative of nitrogen mustard (melphalan), has been investigated in LPC-1 plasmacytoma cells in vitro. Evidence suggesting that melphalan uptake is an active process is that uptake of free intact melphalan proceeds "uphill" against a concentration gradient, is temperature- and sodium-dependent, and is inhibited by several metabolic antagonists. Other findings supporting the concept that melphalan uptake is carrier-mediated is that uptake follows biphasic Michaelis-Menten kinetics, is chemically specific, and is mediated by at least two separate amino acid transport systems. Uptake by one system was sensitive to DL-beta-2-aminobicyclo[2,2,1]-heptane-2-carboxylic acid, was sodium-independent, and appeared to be mediated by system L. The second unassigned system was characterized by sodium dependence, insensitivity to 2-aminoisobutyric acid and 2-(methylamino)isobutyric acid, and was inhibited by alanine, serine, cysteine, and other amino acids.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 762115

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

Review 1.  Inner blood-retinal barrier transporters: role of retinal drug delivery.

Authors:  Ken-ichi Hosoya; Masanori Tachikawa
Journal:  Pharm Res       Date:  2009-07-01       Impact factor: 4.200

Review 2.  Prodrug approaches for CNS delivery.

Authors:  Jarkko Rautio; Krista Laine; Mikko Gynther; Jouko Savolainen
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

3.  The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.

Authors:  U Loos; E Musch; M Engel; J H Hartlapp; E Hügl; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat.

Authors:  N H Greig; D J Sweeney; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.

Authors:  Y K Cho; D W Sborov; M Lamprecht; J Li; J Wang; E M Hade; Y Gao; K Tackett; N Williams; D M Benson; Y A Efebera; A E Rosko; S M Devine; M Poi; C C Hofmeister; M A Phelps
Journal:  Clin Pharmacol Ther       Date:  2017-05-26       Impact factor: 6.875

6.  Evaluation of p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met-ethoxy HCl against transplantable and spontaneous murine neoplasia.

Authors:  M J Yagi; J G Bekesi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  Effects of amino acids on the transport and cytotoxicity of melphalan by human bone marrow cells and human tumor cells.

Authors:  M Dufour; L C Panasci; J St Germain; L Boulet
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  Effect of administration of sodium cyanate and melphalan on the lifespan of P388 tumor-bearing CD2F1 mice.

Authors:  M Dufour; J St Germain; V Skalski; A Dorato; P Lazarus; L C Panasci
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

9.  The effect of dietary amino acids on the gastrointestinal absorption of melphalan and chlorambucil.

Authors:  C G Adair; J C McElnay
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections.

Authors:  Suresh Katragadda; Sriram Gunda; Sudharshan Hariharan; Ashim K Mitra
Journal:  Int J Pharm       Date:  2008-03-22       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.